Cover
Cover | Oct. 29, 2020 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | In accordance with Instruction No. 2 to Item 5.02 of Form 8-K, Eagle Pharmaceuticals, Inc., or the Company, is filing this Current Report on Form 8-K/A, or the Amendment Filing, to amend the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on November 2, 2020, or the Original Filing. Except as expressly set forth herein, this Amendment Filing does not amend, modify or update the disclosures contained in the Original Filing. |
Document Period End Date | Oct. 29, 2020 |
Entity File Number | 001-36306 |
Entity Registrant Name | Eagle Pharmaceuticals, Inc. |
Entity Central Index Key | 0000827871 |
Entity Tax Identification Number | 20-8179278 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 50 Tice Boulevard |
Entity Address, Address Line Two | Suite 315 |
Entity Address, City or Town | Woodcliff Lake |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07677 |
City Area Code | 201 |
Local Phone Number | 326-5300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock (par value $0.001 per share) |
Trading Symbol | EGRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |